Enteropathy-associated T-cell lymphoma
MONDO:0019473An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is seen with increased frequency in regions with a high prevalence of celiac disease.
Also known as: EATL, EATL, type I, ETTL, enteropathy associated T-cell lymphoma, enteropathy-associated T-cell lymphoma, type I, enteropathy-type T-cell lymphoma, intestinal T-cell lymphoma, EATCL
1947 clinical trials for this condition and its sub-types, 20 tagged with Enteropathy-associated T-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Enteropathy-associated T-cell lymphoma
-
Can a powerful combo of drugs and stem cell transplant beat tough lymphomas in kids?
Cure Recruiting nowThis trial is testing a two-step approach for children, teens, and young adults with advanced T-cell or NK-cell lymphoma or leukemia. First, patients receive a combination of chemotherapy and immunotherapy drugs to shrink the cancer. Then, those who respond go on to receive a ste…
Early phase 1 • Sponsor: New York Medical College • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
New drug cocktail aims to boost remission in tough lymphoma
Disease control Recruiting nowThis phase II trial tests whether adding either duvelisib or oral azacitidine to standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma that have not been treated yet. About 170 participants will receive one of three treatment combinat…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Gene therapy trial targets tough T-Cell cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…
Phase 3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for rare blood cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called DR-01 in adults with rare types of leukemia or lymphoma. The goal is to see if it is safe and can shrink tumors. About 200 people will take part in this early-stage trial.
Phase 1/2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for rare lymphoma in Real-World study
Disease control Recruiting nowThis observational study tracks 100 adults in Spain with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin plus CHP as their first treatment. Researchers will review medical records to see how long patients live without their cancer getting worse, how well…
Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC